🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Elias Jabbour

The University of Texas MD Anderson Cancer Center

ORCID: 0000-0003-0946-1519

MedicineSocial Sciences

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

2in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 5 papers. Top paper: “Evolution of decitabine development”.

Evolution of decitabine development

Cancer(2008)10.1002/cncr.23463

N/A

0.815DataRank · unranked

228 citations

Jean‐Pierre Issa, Guillermo Garcia‐Manero, Hagop Kantarjian, Elias Jabbour

Molecular characterization and predictors of relapse in patients with Ph + ALL after frontline ponatinib and blinatumomab

Journal of Hematology & Oncology(2025)10.1186/s13045-025-01709-y

N/A

0.471DataRank · unranked

17 citations

Hagop Kantarjian, Ken Furudate, Nitin Jain, Farhad Ravandi, Omer Karrar +8 more

Antibody based therapy in relapsed acute lymphoblastic leukemia

Best Practice & Research Clinical Haematology(2020)10.1016/j.beha.2020.101225

N/A

0.312DataRank · unranked

7 citations

Serena Chew, Elias Jabbour, Hagop Kantarjian, Nadya Jammal

SOHO State of the Art Updates and Next Questions | Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Can Be Treated with Chemotherapy-Free Regimens without Transplant

Clinical Lymphoma Myeloma & Leukemia(2025)10.1016/j.clml.2025.06.019

N/A

0DataRank · unranked

0 citations

Hagop M. Kantarjian, Jayastu Senapati, Nitin Jain, Nicholas J. Short, Elias Jabbour +1 more

SOHO State of the Art Updates and Next Questions | Choosing the Best Frontline BCR::ABL1 Tyrosine Kinase Inhibitor in Chronic Myeloid Leukemia—How to Define the Treatment Value?

Clinical Lymphoma Myeloma & Leukemia(2025)10.1016/j.clml.2025.10.001

N/A

0DataRank · unranked

0 citations

Elias Jabbour, Massimo Breccia, Rüdiger Hehlmann, Hemant Malhotra, Franck E. Nicolini +3 more